Cota, Inc.

Cota, Inc. develops innovative oncology data solutions that leverage real-world patient data to enhance cancer care, focusing on improving research and development outcomes for healthcare stakeholders. Cota, Inc. specializes in oncology data solutions, providing insights derived from extensive datasets.

Founded in 2011 in New York, US, by Andrew Pecora, the company has completed 7 deals, with its most recent funding round, Series D, occurring on October 25, 2022, raising USD 34. 00 mn from investors such as Baptist Hospital of Miami and Boston Millennia Partners. The company operates without any known subsidiaries or major structural pivots. Cota Healthcare specializes in providing a comprehensive suite of oncology data solutions aimed at transforming cancer care through the use of real-world patient data.

Their core offerings include detailed longitudinal datasets that encompass over 2 million patients across various cancer diagnoses and treatment settings. These datasets assist pharmaceutical and biotech companies in optimizing their research, development, and commercialization strategies by providing insights into patient outcomes across diverse subpopulations and oncology disease areas. COTA's services include expert clinical insights, study design support, and statistical analysis, catering primarily to oncology research and development teams, regulatory bodies, commercial entities, and health economics and outcomes research (HEOR) professionals. The company operates in multiple geographical markets, including North America and Europe, effectively serving clients who require high-quality and reliable cancer patient datasets for their research initiatives.

Cota Healthcare generates revenue through partnerships and subscriptions with organizations in the healthcare sector, including pharmaceutical and biotech companies. Revenue transactions involve clients gaining access to Cota’s curated datasets and analytical services under a structured subscription model, allowing these organizations to leverage the data for their research and development efforts. The service offerings consist of customizable packages tailored to the specific needs of each client, providing varying levels of access to the extensive database of cancer patient data and analytical support. By supplying actionable insights, Cota positions its clients to enhance their research outcomes and market strategies, establishing a mutually beneficial relationship.

Following its latest funding round on October 25, 2022, Cota, Inc. plans to utilize the USD 34. 00 mn raised to further grow its platform and services and boost drug development in oncology. The company is focused on expanding its offerings and aims to enhance its capabilities in oncology data solutions.

Specific details on upcoming product launches or entry into new markets have not been disclosed.